MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.84
-0.13 (-2.18%)
At close: Dec 19, 2025, 4:00 PM EST
6.06
+0.22 (3.77%)
After-hours: Dec 19, 2025, 7:59 PM EST
MannKind Employees
As of December 31, 2024, MannKind had 407 total employees, including 403 full-time and 4 part-time employees. The number of employees decreased by 7 or -1.69% compared to the previous year.
Employees
407
Change (1Y)
-7
Growth (1Y)
-1.69%
Revenue / Employee
$770,975
Profits / Employee
$71,826
Market Cap
1.79B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 407 | -7 | -1.69% |
| Dec 31, 2023 | 414 | 19 | 4.81% |
| Dec 31, 2022 | 395 | 46 | 13.18% |
| Dec 31, 2021 | 349 | 108 | 44.81% |
| Dec 31, 2020 | 241 | 8 | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MNKD News
- 18 days ago - MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients - Seeking Alpha
- 20 days ago - MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - GlobeNewsWire
- 5 weeks ago - MannKind to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript - Seeking Alpha
- 5 weeks ago - MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease - GlobeNewsWire
- 6 weeks ago - MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes - GlobeNewsWire
- 6 weeks ago - MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire